Survival in Recipients of Marginal Cadaveric Donor Kidneys Compared with Other Recipients and Wait-Listed Transplant Candidates

Transcription

1 J Am Soc Nephrol 12: , 2001 Survival in Recipients of Marginal Cadaveric Donor Kidneys Compared with Other Recipients and Wait-Listed Transplant Candidates AKINLOLU O. OJO,* JULIE A. HANSON,* HERWIG-ULF MEIER-KRIESCHE,* CHIKE N. OKECHUKWU,* ROBERT A. WOLFE, ALAN B. LEICHTMAN,* LAWRENCE Y. AGODOA, BRUCE KAPLAN,* and FRIEDRICH K. PORT* Departments of *Medicine, Biostatistics, and Epidemiology, University of Michigan, Ann Arbor, Michigan; and The United States Renal Data System, Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. Abstract. An increasing number of cadaveric kidney transplants are now performed with organs from donors who would have been deemed unsuitable in earlier times. Although good allograft outcomes have been obtained with these marginal donor transplants, it is unclear whether recipients of marginal kidney transplants achieve a reduction in long-term mortality as do recipients of ideal kidneys. Patients with end-stage renal disease registered on the cadaveric renal transplant waiting list between January 1, 1992, and June 30, 1997, were studied for mortality risks according to three outcomes: waitlisted on dialysis treatment with no transplant (WLD); transplantation with marginal donor kidney (MDK); and ideal or optimal donor kidney transplantation (IDK). Thirty-four percent of wait-list registrants had received a cadaveric kidney transplant by June 30, Of these, 18% received a marginal kidney that had one or more of the following pretransplant factors: donor age 55 yr, non-heartbeating donor, cold ischemia time 36 h, and donor hypertension or diabetes mellitus of 10 yr duration. Five-year graft and patient survival was 53% and 74% for MDK recipients compared with 67% (P 0.001) and 80% (P 0.001) for IDK recipients. Adjusted annual death rate and estimated remaining life time was 6.3%, 4.7%, and 3.3% and 15.3 yr, 20.4 yr, and 28.7 yr for WLD, MDK, and IDK groups, respectively. The average increase in life expectancy for MDK recipients compared with the WLD cohort was 5 yr, although this benefit varied from 3 to 10 yr depending on the recipient s characteristics. It is concluded that transplantation of a marginal kidney is associated with a significant survival benefit when compared with maintenance dialysis. One strategy that has been used to address the perennial and increasingly critical shortage of kidneys for transplantation is the expansion of the cadaveric kidney donor pool to include those who might have been deemed unsuitable in earlier times (1 5). Increasing donor age is a major determinant of graft outcome (4,6 9), yet the number of older cadaveric donors ( 50 yr), as a fraction of all kidney transplants in the United States, increased from 12.1% in 1988 to 26.1% in 1996 (10). There is no universal definition of what constitutes an ideal or marginal transplantable kidney. However, the presence of certain pretransplant correlates of diminished graft survival, such as advanced donor age, long-standing donor hypertension or diabetes mellitus, non-heartbeating cadaver donor (NHBD), Received March 10, Accepted July 28, Correspondence to Dr. Akinlolu O. Ojo, Division of Nephrology, TC 3914, Box 0364, Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI Phone: ; Fax: ; aojo@umich.edu / Journal of the American Society of Nephrology Copyright 2001 by the American Society of Nephrology and prolonged cold preservation time (5,11 19), have been used to characterize an organ as being of marginal quality. In most series, allograft outcomes with marginal kidneys are inferior to that of organs considered to be ideal (15,20 25). Notwithstanding the diminished graft survival of marginal kidneys, renal transplantation improves quality of life (26 30) and economic analysis suggests that transplantation with a marginal donor kidney is more cost-effective than dialysis treatment (31). Improved patient survival is a well-established benefit of renal transplantation, but the magnitude of increased longevity is not uniform across patient subgroups (32 36). For example, following the excess initial mortality associated with the transplant procedure, the cumulative time to equal mortality between transplant recipients and their wait-listed counterparts (those who remain on dialysis) range from 57 d in recipients aged 20 to 39 yr to 369 d in recipients aged 60 to 74 yr (33,35). The estimated additional life-years gained from renal transplantation vary from 8 yr in a diabetic recipient who is 60 yr or older to 31 yr in a nondiabetic recipient who is 20 to 44 yr old (33,35). Thus, any survival advantage to be gained from receiving a marginal donor kidney is also likely to vary between subgroups of recipients. If there is substantial variability in

2 590 Journal of the American Society of Nephrology J Am Soc Nephrol 12: , 2001 patient survival with marginal donor kidney transplantation, then it stands to reason that some patients may benefit (in the strict sense of average patient survival) from receiving a marginal kidney, whereas others may not. We previously showed that allograft loss terminates the patient survival benefit accruable from kidney transplantation such that patients who lose graft function are at increased mortality risk unless repeat transplantation is performed (37). Because marginal organs have comparatively diminished allograft survival, we ask whether it is actuarially beneficial for a patient who is on the cadaveric renal transplant waiting list to accept or decline an offer for transplantation with an organ that has one or more characteristics associated with diminished graft survival, i.e., marginal donor kidney. To address this question, we conducted a historical prospective cohort analysis of U.S. national data in which the survival of recipients of marginal kidneys was compared with two groups of patients: wait-listed dialysis patients and recipients of ideal cadaveric donor kidneys (IDK). Materials and Methods Patients We identified patients who were awaiting cadaveric renal transplantation in the U.S. Scientific Renal Transplant Registry database, which was supplied by the United Network for Organ Sharing (UNOS). Dialysis treatment history for the wait-listed patients was obtained from the U.S. Renal Data System (USRDS). Vital status was determined from the USRDS patient data files. A longitudinal analysis file was constructed to track patients after waiting list registration while on dialysis and/or after receiving a cadaveric renal transplant between January 1, 1992, and June 30, A total of 122,175 patients were registered on the UNOS renal transplant waiting list during the study period. Waiting list registrants who received multiorgan (n 2000) or living donor renal transplant (n 6988) were censored from further analysis. For repeat transplant recipients as well as repeat transplant candidates, the study start date was taken to be the date of waiting list registration for the index (most recent) kidney transplantation. Those who received a cadaveric renal transplant were divided into two groups (marginal kidney recipients and ideal kidney recipients) on the basis of the characteristics of the organ received. This classification was based on the following definition. A recipient was defined as receiving a marginal donor kidney (MDK) if one or more of the following pretransplant factors was present: donor age 55 yr, donor history of hypertension longer than 10 yr duration, donor history of diabetes mellitus longer than 10 yr duration, NHBD, and cold preservation time 36 h. A cadaveric kidney transplant in which none of the listed factors was evident was defined as an IDK. All patients were on the waiting list and most (97%) were on dialysis treatment (WLD) for some time until transplantation or end of follow-up. The number of IDK and MDK recipients studied were 34,438 and 7,454, respectively. The two groups of cadaveric transplant recipients and the WLD patients were followed until the earliest of death or June 30, As would be expected, exit from the waiting list for medical reasons often preceded death; therefore, patients who were removed from the waiting list were not censored to avoid bias due to informative censoring. Because failure to show up for nonmedical reasons is a rare cause of turning down an allocated kidney, patients who did not receive an assigned organ for nonmedical reasons were also left in the waiting list cohort. Patient survival was analyzed in an intention-to-treat manner with the time-dependent, nonproportional Cox regression technique while adjusting for baseline characteristics including age, race, cause of end-stage renal disease (ESRD) and time spent on the waiting list. Cox-adjusted relative mortality risk of transplant recipients was calculated for separate groups after transplantation using WLD as the reference group. Time to equal mortality risk, time to cumulative equal survival (i.e., when equal proportions are dead in both groups), and expected remaining life-years were calculated for different patient subgroups according to the methods previously described by Mauger et al. (38) and Wolfe et al. (35,39). Graft survival was estimated with the Cox nonproportional regression in which recipients were stratified by donor type (MDK versus IDK) such that the logarithmic hazard ratio between the two groups was allowed to be nonparallel. Delayed graft function was defined as one or more dialysis treatments in the first week after transplantation. Acute rejection was noted to have occurred when reported by the individual transplant center to the Renal Transplant Scientific Registry. Graft survival estimates were compared by the log likelihood ratio test. The t and Mantel-Haenszel 2 tests were used for univariate analysis. A P value of 0.05 was considered significant. Statistical analysis was performed with SAS software (SAS, version 6.12, Cary, NC). Results Of the 122,175 candidates registered for renal transplantation between January 1, 1992, and June 30, 1997, 41,892 (34%) received a cadaveric kidney transplant by June 30, During this period, 7125 (14%) of the kidney transplant recipients died compared with 38.3% of deaths in candidates who remained wait-listed without a kidney transplant (P 0.001). Eighteen percent of cadaveric renal recipients met the criteria for marginal donor kidney transplantation, and the remainder (82%) met the criteria for ideal kidney transplantation. Table 1 shows the demographic characteristics and baseline transplant variables in these two groups of cadaveric kidney transplant recipients. Recipients of MDK were older than ideal kidney transplant recipients (47 yr versus 43 yr; P 0.01). Blacks, males, and diabetics were more likely to receive IDK than MDK transplantation. There was no significant difference between MDK and IDK recipients in the proportion of recipients who underwent repeat transplantation (13.5% versus 14%; P 0.35). Donor cause of death was predominantly cerebrovascular accident in the MDK recipients (62.9%) as compared with IDK recipients in whom the predominant donor cause of death was head trauma (41.1%). The most common factor for being classified as a marginal donor was donor age 55 yr, which was present in 63.8% of MDK. Donor hypertension 10 yr, donor diabetes mellitus 10 yr, cold ischemia time 36 h, and NHBD were present in 10.5%, 1.3%, 31.1%, and 4.7% of cases, respectively. Graft Survival Graft failure, defined as return to maintenance dialysis or graft nephrectomy, was more frequent in MDK recipients (35.9%; n 2678) compared with 24.9% (n 8581) of graft failures in IDK recipients (P 0.001). Correspondingly, the adjusted 5-yr graft survival (Figure 1) was significantly lower in the MDK compared with the IDK recipients (59% versus

3 J Am Soc Nephrol 12: , 2001 Survival in Expanded Donor Kidney Recipients 591 Table 1. Baseline characteristics in 41,892 renal transplant recipients: 1992 to 1998 a Characteristic Marginal Kidney Recipients (N 7454) Ideal Kidney Recipients (N 34,438) P Value Recipient age at transplant (mean SD) Recipient gender (male:female) 62.0: : Recipient race [% (n)] white 65.5 (4,885) 68.4 (23,491) black 27.5 (2,053) 25.3 (8,638) other 6.9 (526) 6.3 (2,086) 0.29 Primary cause of ESRD [% (n)] glomerulonephritis 22.9 (1,707) 21.7 (7,480) 0.03 hypertension 20.1 (1,498) 18.1 (6,239) diabetes mellitus 22.3 (1,659) 25.6 (8,809) cystic kidney disease 6.2 (463) 5.5 (1,881) 0.01 other 28.5 (2127) 29.1 (10,029) 0.97 Donor gender (male:female) 51.1: : Donor race [% (n)] white 89.6 (6,654) 85.7 (29,081) black 8.1 (605) 12.0 (4,078) other 2.3 (169) 2.3 (790) 0.89 Primary transplant [% (n)] 86.5 (6,445) 86.0 (29,633) 0.35 Months of dialysis before transplantation [% (n)] 0 (preemptive) 8.1 (600) 10.0 (3,426) (408) 6.3 (2,145) (827) 11.8 (4,021) (1,788) 23.2 (7,936) (3,791) 48.8 (16,687) Most recent PRA level [% (n)] 0 % 65.5 (4,885) 65.6 (22,604) % 18.2 (1,358) 18.3 (6,285) % 6.2 (462) 5.7 (1,955) % 7.1 (528) 7.7 (2,638) 0.08 Donor cause of death [% (n)] anoxic 7.1 (531) 7.5 (2,582) 0.26 CVA/stroke 62.9 (4,691) 29.9 (10,280) head trauma 17.8 (1,325) 41.1 (14,164) CNS tumor 0.5 (38) 0.7 (230) 0.09 miscellaneous 11.2 (832) 19.3 (6,646) missing/unknown 0.5 (37) 1.6 (536) a ESRD, end-stage renal disease; PRA, panel-reactive antibody; CVA, cerebrovascular accident; CNS, central nervous system. 72%; P 0.001). Among MDK recipients, the 5-yr graft survival was highest in the other race group (65%) compared with 62% in white (P 0.001) and 49% in black recipients (P 0.001). The risk factors for graft survival as obtained from multivariate analysis are shown in Table 2. Patient Survival The primary objective of the study was to determine whether patients who received a marginal donor kidney transplant have a different survival experience compared with their wait-listed counterparts. In this study cohort, the average death rate adjusted for age, race, gender, and cause of death for wait-listed patients was 6.3% per year, which was significantly higher than the average adjusted death rate in MDK recipients (4.7%/ yr; P 0.001) and IDK recipients (3.3%/yr; P 0.001). The adjusted 5-yr patient survival was higher in IDK recipients compared with MDK recipients (85% versus 77%; P 0.001). Figure 2 depicts the mortality experience of MDK and IDK kidney transplant recipients up to 700 d posttransplantation. At all times during follow-up, IDK recipients had lower mortality risks compared with MDK recipients. The time to equal mortality risk, i.e., how long it took the excess risk due to the transplant procedure to dissipate, was 185 d and 122 d for MDK and IDK recipients, respectively (P 0.001). In these

4 592 Journal of the American Society of Nephrology J Am Soc Nephrol 12: , 2001 Figure 1. Adjusted 5-yr renal allograft survival according to cadaveric donor classification: marginal versus ideal donor. f, ideal donor kidney (72%);, marginal donor kidney (59%). adjusted analyses, the same proportion of transplant recipients and wait-listed patients on dialysis were dead by 531 d posttransplantation for MDK and 256 d posttransplantation for IDK recipients. According to the time-dependent Cox regression analysis, the expected life-years for wait-listed, never transplanted dialysis patients was 15.3 yr compared with 20.4 yr for MDK recipients (P 0.001) and 28.7 yr for IDK recipients (P 0.001). Thus, transplantation with a marginal kidney increased life expectancy by 5.1 yr over maintenance dialysis treatment, whereas the increase in life expectancy was 13.4 yr for ideal kidney transplant recipients. Compared with WLD, long-term relative mortality risk was lower by 25% (relative risk [RR] 0.75, P 0.001) and 48% (RR 0.52, P 0.001) for MDK and IDK recipients, respectively. Adjusted estimates of mortality risks in subgroups of marginal kidney transplant recipients are shown in Table 3. Annual death rates among WLD ranged from 2.2% for the age group 18 to 29 yr to 10.0% for patients for the age group 65 yr. Annual death rates on the waiting list also vary by race and cause of ESRD, with black patients having a lower death rate compared with white patients (4.8% versus 7.5%; P 0.001) and patients with end-stage diabetic nephropathy having a death rate that was much higher than other causes of ESRD (10.8% versus 4.3%; P 0.001). The underlying variability in mortality on the waiting list was reflected in the relative magnitude of the additional life-years gained with marginal kidney transplantation. Recipients in the youngest age group studied had the longest improvement in survival (6.4 yr) compared with 3.8 yr in the oldest recipient age group ( 65 yr). However, the proportional benefit was not significant for the younger age groups (RR 0.85, P 0.55 for age group 18 to 29 yr and RR 0.78, P 0.09 for age group 30 to 44 yr) when compared with their WLD counterparts. In contrast, older recipients ( 65 yr) had a significant proportional increase in longevity (RR 0.71, P 0.03). Similarly, better survival in black patients on the waiting list was reflected in nonsignificant proportional improvement following MDK (RR 0.86, P 0.13), whereas white patients who had lower survival on dialysis (7.5% versus 4.3% in black patients) had proportional significant improvement in post-mdk transplant survival (RR 0.68, P 0.001). Compared with white recipients, the gain in life expectancy for black MDK recipients was marginally lower (3.1 versus 5.9 yr; P 0.09). Table 4 shows the prognostic indicators for patient survival according to the multivariate nonproportional Cox regression analysis. Among the four characteristics used to define an MKD, only the donor age was predictive of patient survival (5-yr mortality increased by 5% for each decade increase in donor age; P 0.001). Other variables independently associated with patient survival were recipient age and race, primary cause of ESRD, and panel reactive antibody greater than 30% at the time of transplantation. There was no interactive effect of donor and recipient age on patient survival. Discussion Substantial evidence supports the notion that marginal kidney transplants have lower allograft outcomes compared with an ideal cadaveric kidney transplant. In this study, marginal kidney transplantation was associated with substantial reduction in mortality and improvement in life expectancy when compared with transplant candidates who remained on maintenance dialysis treatment. On the average, recipients of marginal kidney transplants lived 5 yr longer than transplant candidates who remained on dialysis, whereas ideal cadaveric transplant recipients had a 13-yr survival benefit. As is the case with the latter, the survival benefit of marginal donor kidney

5 J Am Soc Nephrol 12: , 2001 Survival in Expanded Donor Kidney Recipients 593 Table 2. Risk factors for graft survival in cadaveric renal transplant recipients: 1992 to 1998 a Variable (Reference Group) Relative Risk (95% CI) P Value Donor age (7 11 yr) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Donor age (per decade) 1.06 ( ) Donor hypertension 10 yr 1.17 ( ) 0.03 Donor diabetes mellitus 10 yr 0.73 ( ) 0.22 Non-heartbeating donor 0.85 ( ) 0.16 Male donor 0.94 ( ) Donor race (White) black 1.30 ( ) other 1.15 ( ) Delayed graft function 1.99 ( ) Acute rejection in the first 6 mo 1.32 ( ) Recipient age (per decade) 1.08 ( ) Recipient race (white) black 1.30 ( ) other 0.86 ( ) Cause of ESRD (glomerulonephritis) diabetes mellitus 1.17 ( ) hypertension 1.13 ( ) cystic kidney disease 0.74 ( ) PRA 30% (0%) 1.21 ( ) Repeat transplant (first transplant) 1.27 ( ) a Other independent predictors of graft survival in the Cox regression model were donor recipient cytomegalovirus match and year of transplantation. transplantation varied by cause of ESRD, recipient age, and race. Patients with end-stage diabetic nephropathy had the greatest proportional benefit from MDK transplantation (RR 0.62; extra life-years 5.6 yr), whereas patients with ESRD from hypertension had the longest numerical increase in life expectancy (8.5 yr). Among the different age groups, recipients aged 55 to 64 yr had the greatest survival benefit of 7.3 yr (RR 0.66; P ). The survival benefit in younger recipients (aged 18 to 54) was mitigated by their relatively lower mortality risks on the waiting list. However, these younger age groups gained an additional 5 to 6.5 life-years compared with their wait-listed counterparts. The life expectancy for wait-listed black patients was 20 versus 13 yr in white patients. However, posttransplantation increase in life expectancy was greater for white than for black recipients (6 versus 3 yr). Our finding of significantly lower mortality in wait-listed black patients (compared with white patients) is consistent with previous studies that showed lower mortality rates in black patients in the general dialysis population (40 42). One possible explanation for this finding is that the previously observed lower overall renal transplantation rates and longer waiting times for black patients (43 46) leads to a disproportionate enrichment of a black wait-listed dialysis cohort with the patients who have lower burden of comorbid conditions and are thus likely to live longer. That the greatest increase in life expectancy was observed for recipients of other race (10 yr) who had an intermediate death rate (6.3%/yr) on dialysis suggests that other factors independent of the determinants of dialysis survival were responsible for posttransplantation patient survival. Indeed, we found that the 5-yr graft survival for marginal kidney transplants (an indicator of the probability of return to dialysis and therefore greater mortality hazard) was poorest in black recipients (46%), intermediate in white recipients (60%), and highest in the other recipient race group (65%). Notwithstanding the subgroup differences in the patient outcomes with marginal kidney transplantation, it is important to reinforce the perspective that successful kidney transplantation with ideal or marginal organs is associated with dramatic and substantial improvement in quality of life (26 30). Moreover, receipt of a marginal kidney transplant was not detrimental to patient survival in any subgroup that we examined.

6 594 Journal of the American Society of Nephrology J Am Soc Nephrol 12: , 2001 Figure 2. Mortality risks in two groups of cadaveric renal transplant recipients relative to wait-listed dialysis patients. Table 3. Mortality risks in marginal donor kidney recipients relative to wait-listed dialysis patients Patient Group Annual Death Rate Among WLD (%) Days to Equal Risk Days to Equal Survival RR a (P Value) Projected Extra Lifetime (yr) All Age (yr) Race white black other Gender male female Cause of ESRD glomerulonephritis hypertension diabetes mellitus other diagnoses a Relative mortality in marginal donor kidney recipients 5 yr after transplantation. Whereas several investigators have reported on allograft outcomes with marginal kidney transplantation, this study, to our knowledge is the first attempt to examine the patient survival in recipients of marginal kidney transplant. The results should help to clarify whether to accept a marginal kidney. Often, in practice, the transplant physician weighs this question in addition to several other factors before offering a marginal organ to a particular recipient. Should the transplant physician,

7 J Am Soc Nephrol 12: , 2001 Survival in Expanded Donor Kidney Recipients 595 Table 4. Risk factors for survival in recipients of cadaveric renal transplantation: 1992 to 1998 Variable (Reference Group) Relative Risk (95% CI) P Value Donor age (per decade) 1.05 ( ) Donor hypertension 10 yr 1.09 ( ) 0.40 Donor diabetes mellitus 10 yr 0.90 ( ) 0.77 Non-heartbeating donor 0.89 ( ) 0.45 Delayed graft function 1.64 ( ) Acute rejection in the first 6 mo 1.20 ( ) Renal allograft failure 2.23 ( ) Recipient age (per decade) 1.40 ( ) Recipient race (white) black 0.94 ( ) 0.05 other race 0.72 ( ) Cause of ESRD (glomerulonephritis) diabetes mellitus 1.80 ( ) hypertension 1.18 ( ) cystic kidney disease 0.78 ( ) PRA 30% (0%) 1.34 ( ) Repeat transplant (first transplant) 0.97 ( ) 0.51 CMV match ( D 3 R) D 3 R 1.23 ( ) D 3 R 1.10 ( ) 0.45 D 3 R 1.14 ( ) potential recipient, or both make this determination at the time of organ availability or should this prospect be discussed at the time of transplant evaluation? This needs to be clarified with studies taking into account all of the factors that often come into play when this type of decision is confronted. The perspective informed by the present study does not entail the choice between an ideal or a marginal kidney because this is muted by the well-established fact that, in general, cadaveric kidney transplantation is life saving (35). Of note is that in the subset of kidney transplants for which preterminal donor renal function data were available, serum creatinine was higher for MDK versus IDK ( mg/dl versus mg/dl). This implies that other clinical data such as histologic appearance and level of proteinuria may be more pertinent to outcomes (13,47,48). Our study suggests that such data are often used to discriminate which marginal kidneys are suitable for implantation. Thus, our results support critical assessment of the suitability of compromised cadaveric donor kidneys as opposed to liberal expansion of donor criteria. The analysis presented here has a number of limitations. First, we cannot be certain that recipients of marginal donor organs were not specifically selected because the baseline characteristics were dissimilar to that of recipients of ideal cadaveric kidneys with respect to certain important prognostic factors. For example, compared with ideal kidney transplant recipients, the recipients of marginal kidneys were older (47 versus 43 yr; P 0.001) and less likely to have had end-stage diabetic nephropathy (22 versus 26%; P 0.001). Thus, the beneficial outcomes observed in marginal kidney transplant recipients may have resulted from implicit donor recipient matching within the confines of organ allocation policy. Therefore, the result may not be applicable to the average renal transplant candidate. Second, as noted above, we relied on donor age, cold storage time, duration of hypertension and diabetes, and NHBD status to define organ suitability. These factors are not as comprehensive and are not as proximate and precise as detailed histologic and functional analysis of donor kidneys as determinants of organ suitability. Last, this study examined the survival benefit of kidney transplantation with a marginal donor organ but did not address the survival effect of receiving an MDK versus remaining on the waiting list after turning down such a kidney. In summary, transplantation with organs that fulfill expanded donor criteria account for almost one fifth of cadaveric renal transplantation in recent years. The expanded donor now represents the largest growth in transplantable cadaver kidneys in the United States. The present study demonstrates that the use of such marginal kidneys prolongs the life of the recipient. The gains in life expectancy vary markedly from 3 to 9 yr depending on the characteristics of recipients. To determine whether any subgroup of patients benefits more than others requires a more comprehensive assessment of adjusted quality life-years and assignment of utilitarian values balanced with equity considerations. A prospective evaluation of these issues is warranted to determine whether careful donor recipient matching of marginal cadaveric kidneys can maximize the efficiency of the organ allocation system. Acknowledgments This work was supported by NIH grant 5 K08 DK02519 awarded to A. O. Ojo.

8 596 Journal of the American Society of Nephrology J Am Soc Nephrol 12: , 2001 References 1. Plotkin JS, Ridge L, Kuo PC, Lim J, Njoku MJ, Johnson LB: Extending the boundaries of acceptable organ donors: A means of expanding the donor pool for liver transplantation. Transplant Proc 29: 3288, Ratner LE, Kraus E, Magnuson T, Bender JS: Transplantation of kidneys from expanded criteria donors. Surgery 119: , Smith RB, Fairchild R, Bradley JW, Cho SI: Cadaver kidney donors with hypertensive histories. Transplant Proc 20: , Alexander JW, Vaughn WK, Carey MA: The use of marginal donors for organ transplantation: The older and younger donors. Transplant Proc 23: , Vromen MA, Leunissen KM, Persijn GG, Kootstra G: Short- and long-term results with adult non-heart-beating donor kidneys. Transplant Proc 20: , Pokorná E,Vítko S, Chadimová M, Schück O, Ekberg H: Proportion of glomerulosclerosis in procurement wedge biopsy cannot alone discriminate for acceptance of marginal donors. Transplantation 69: 36 43, Terasaki PI, Gjertson DW, Cecka JM, Takemoto S, Cho YW: Significance of the donor age effect on kidney transplants. Clin Transplant 11: , Rao KV, Kasiske BL, Odlund MD, Ney AL, Anderson RC: Influence of cadaver donor age on posttransplant renal function and graft outcome. Transplantation 49: 91 95, Hariharan S, McBride MA, Bennett LE, Cohen EP: Risk factors for renal allograft survival from older cadaver donors. Transplantation 64: , Kaufman HM, McBride MA, Rosendale JD, Ellison MD, Daily OP, Wolf JS: Trends in organ donation. Recovery and disposition: UNOS Data for Transplant Proc 29: , Sánchez-Fructuoso AI, Prats D, Torrente J, Pérez-Contín JM, Fernández C, Alvarez J, Barrientos A: Renal transplantation from non-heart beating donors: A promising alternative to enlarge donor pool. J Am Soc Nephrol 11: , Tullius SG, Reutzel-Selke A, Nieminen-Kelha M, Jonas S, Egermann F, Heinzelmann T, Bechstein WO, Volk HD, Neuhaus P: Contribution of donor age and ischemic injury in chronic renal allograft dysfunction. Transplant Proc 31: , Remuzzi G, Grinyò J, Ruggenenti P, Beatini M, Cole EH, Milford EL, Brenner BM: early experience with dual kidney transplantation in adults using expanded donor criteria. JAmSoc Nephrol 10: , Alexander JW, Bennett LE, Breen TJ: Effect of donor age on outcome of kidney transplantation. Transplantation 57: , Kuo PC, Johnson LB, Schweitzer EJ, Alfrey EJ, Waskerwitz J, Bartlett ST: Utilization of the older donor for renal transplantation. Am J Surg 172: , Donnelly PK, Henderson R, Price D: Professional attitudes to bioethical issues ration the supply of marginal living donor kidneys for transplantation. Transplant Proc 31: , Roels L, Vanrenterghem Y, Waer M, Christiaens M, Gruwez J, Michielsen P: The aging kidney donor: Another answer to organ shortage? Transplant Proc 22: , Cho YW, Cecka JM, Gjertson DW, Terasaki PI: Prolonged hypertension ( 10 years) is a significant risk factor in older cadaver donor renal transplants. Transplant Proc 31: 1283, Shenoy S, Lowell JA, Flye MW, Brennan DC, Ceriotti C, Howard TK: Use of extended donors in high-risk renal transplant recipients: A 2-year single-center experience. Transplant Proc 28: 95, Golconda MS, Whiting JF, Smith R, Hayes R, Alexander JW, First MR: Long-term outcome of kidney transplantation from expanded criteria donors: A single center experience. Transplant Proc 29: , Rosenthal JT, Misertino DP, Mendez R, Koyle MA: Extending the criteria for cadaver kidney donors. Transplant Proc 22: , Vivas CA, O Donovan RM, Jordan ML, Hickey DP, Hrebinko R, Shapiro R, Starzl TE, Hakala TR: Cadaveric renal transplantation using kidneys from donors greater than 60 years old. Clin Transplant 6: 77 80, Berardinelli L, Pasciucco A, Pozzoli E, Ferraresso M, Carini M, Vegeto A: Kidneys from border-age donors in the cyclosporine era: Long-term function and outcome. Transplant Proc 31: , Mascaretti L, Pappalettera M, Gravame V, Chiecca R, Scalamogna M, Sirchia G: Cadaver kidney transplantation using donors with hypertension in the North Italy transplant program. Transplant Proc 22: 382, Ratner LE, Zibari G, Patel S, Maley WR, Kittur D, Burdick J, Olson J: Transplantation of kidneys from hypertensive cadaveric donors. Transplant Proc 27: , Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50: , Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312: , Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F: Changes in quality of life after renal transplantation. Am J Kidney Dis 32: , Simmons RG, Abress L: Quality-of-life issues for end-stage renal disease patients. Am J Kidney Dis 15: , Russell JD, Beecroft ML, Ludwin D, Churchill DN: The quality of life in renal transplantation: A prospective study. Transplantation 54: , Whiting JF, Zavala EY, Alexander JW, First MR: The costeffectiveness of transplantation with expanded donor kidneys. Transplant Proc 31: , Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ: Impact of cadaveric transplantation on survival in end-stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 9: , Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K: Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270: , Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP: Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 24: 59 64, Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: , 1999

9 J Am Soc Nephrol 12: , 2001 Survival in Expanded Donor Kidney Recipients Schaubel D, Desmeules M, Mao Y, Jeffery J, Fenton S: Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis. Transplantation 60: , Ojo AO, Wolfe RA, Agodoa LY, Held PJ, Port FK, Leaver SF, Callard SE, Dickinson DM, Schmouder RL, Leichtman AB: Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation. Multivariate analyses from the United States Renal Data System. Transplantation 66: , Mauger EA, Wolfe RA, Port FK: Transient effects in the Cox proportional hazards regression models. Stat Med 14: , Wolfe RA, Gaylin DS, Port FK, Held PJ, Wood CL: Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int 42: , US Renal Data System Annual Data Report. Bethesda, MD, The National Institutes Health, National of Institute of Diabetes and Digestive and Kidney Diseases, US Renal Data System Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Renal Data System Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Ayanian JZ, Cleary PD, Weissman JS, Epstein AM: The effect of patients preferences on racial differences in access to renal transplantation. N Engl J Med 341: , Held PJ, Pauly MV, Bovbjerg RR, Newmann J, Salvatierra O Jr: Access to kidney transplantation. Has the United States eliminated income and racial differences? Arch Intern Med 148: , Soucie JM, Neylan JF, McClellan W: Race and sex differences in the identification of candidates for renal transplantation. Am J Kidney Dis 19: , Gaylin DS, Held PJ, Port FK, Hunsicker LG, Wolfe RA, Kahan BD, Jones CA, Agodoa LY: The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA 269: , Spees EK, Orlowski JP, Temple DM: The successful use of marginal cadaveric donor kidneys. Transplant Proc 22: , Pokorná E, Vítko S, Chadimová M: Survival and function of renal graft from a marginal cadaver donor. Transplant Proc 29: , 1997 Access to UpToDate on-line is available for additional clinical information at